The emergence and spread of antibiotic resistance in pathogens is a major impediment to the control of microbial disease. Here, we review mechanisms of quinolone resistance in Pseudomonas aeruginosa, an important nosocomial pathogen and a major cause of morbidity in cystic fibrosis (CF) patients. In this quantitative literature review, we find that mutations in DNA gyrase A, the primary target of quinolones in Gram-negative bacteria, are the most common resistance mutations identified in clinical samples of all origins, in keeping with previous observations. However, the identities of non-gyrase resistance mutations vary systematically between samples isolated from CF patients and those isolated from acute infections. CF-derived strains tend to harbour mutations in the efflux pump regulator nfxB, while non-CF strains tend to bear mutations in the efflux regulator mexR or in parC, which encodes one of two subunits of DNA topoisomerase IV. We suggest that differences in resistance mechanisms between CF and non-CF strains result either from local adaptation to different sites of infection or from differences in mutational processes between different environments. We further discuss the therapeutic implications of local differentiation in resistance mechanisms to a common antibiotic.
BagelS.,
HüllenV., WiedemannB.,
HeisigP.1999; Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli . Antimicrob Agents Chemother 43:868–875
BreidensteinE. B. M.,
KhairaB. K.,
WiegandI.,
OverhageJ.,
HancockR. E.2008; Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrob Agents Chemother 52:4486–4491
CambauE.,
PeraniE.,
DibC.,
PetinonC.,
TriasJ.,
JarlierV.1995; Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 39:2248–2252
CDC2010National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2008 Atlanta, GA: Centers For Disease Control;
D'ArgenioD. A.,
WuM.,
HoffmanL. R.,
KulasekaraH. D.,
DézielE., SmithE. E.,
NguyenH.,
ErnstR. K.,
Larson FreemanT. J.other authors2007; Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 64:512–533
HancockR. E. W.1998; Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 27:Suppl. 1S93–S99
Hoogkamp-KorstanjeJ. A.,
van OortH. J.,
SchipperJ. J.,
van der WalT.1984; Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J Antimicrob Chemother 14:641–645
JakicsE. B.,
IyobeS.,
HiraiK.,
FukudaH.,
HashimotoH.1992; Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa . Antimicrob Agents Chemother 36:2562–2565
KassenR.,
BataillonT.2006; Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nat Genet 38:484–488
KureishiA.,
DiverJ. M.,
BecktholdB.,
SchollaardtT.,
BryanL. E.1994; Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother 38:1944–1952
NöllmannM., CrisonaN. J.,
ArimondoP. B.2007; Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 89:490–499
RauM. H.,
HansenS. K.,
JohansenH. K.,
ThomsenL. E.,
WorkmanC. T.,
NielsenK. F.,
JelsbakL.,
HøibyN.,
YangL.,
MolinS.2010; Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 12:1643–1658
RemoldS. K.,
LenskiR. E.2001; Contribution of individual random mutations to genotype-by-environment interactions in Escherichia coli . Proc Natl Acad Sci U S A 98:11388–11393
RowenD. W.,
DereticV.2000; Membrane-to-cytosol redistribution of ECF sigma factor AlgU and conversion to mucoidy in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Mol Microbiol 36:314–327
SchoefflerA. J.,
BergerJ. M.2005; Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 33:1465–1470
ShorrA. F.2009; Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37:1463–1469